Smilkov, Katarina (2021) Design and formulation aspects of monoclonal antibodies for SARS-CoV-2 treatment. In: Montenegrin International Medical Summit, 14-17 Oct 2021, Podgorica, Montenegro.
![[thumbnail of Presentation.pdf]](/style/images/fileicons/text.png) |
Text
Presentation.pdf Download (2MB) |
|
Text
Final abstract book.pdf Download (860kB) |
|
Text
Raspored MIMS 2.pdf Download (424kB) |
Abstract
The occurrence of SARS-CoV-2 virus at the end of 2019 and the quick progress of the infection to pandemic dimensions, has triggered a major response of (bio)pharmaceutical industries all around the world, aimed at development of vaccines on one side, but also development of specific treatments on the other. Today, almost 2 years after, we count several different types of vaccines, polyclonal, monoclonal, and cocktail antibodies that have been tested and approved for use, with many others entering different clinical stages. Apart from the vaccines, aimed at prevention of the infection and development of severe Coronavirus disease (COVID-19), therapies including monoclonal antibodies can play an important part in COVID-19 treatment.ć
Monoclonal antibodies (mAbs) are a growing class of biologicals that have the ability to specifically bind and neutralize specific antigen, in this case the virus. Since the introduction of the first generation of monoclonal antibodies 35 years ago, the science and technology development has greatly speeded their development and improvement, thus providing valuable therapeutic alternative for many diseases. However, the interest of designing therapeutic antibodies for treatment of infectious diseases was not in the scientific focus until recently. The large number of therapeutic mAbs that are being developed against SARS-CoV-2 virus are thus paving the way for other experience in the treatment of both viral and bacterial infections. MAbs that target SARS-CoV-2 virus can be derived from the B cells of convalescent patients or humanized mice, and processed using recombinant technology, and can be used as a type of passive immunotherapy, that adds to the therapeutic alternatives in COVID-19 treatment. Among the antibodies that are approved for emergency use in USA, the anti-SARS-CoV-2 treatments include bamlanivimab as a monotherapy, and bamlanivimab together with etesevimab, or casirivimab with imdevimab (REGEN-COV) as a combination therapy for treatment of non-hospitalized patients with mild-to-moderate COVID-19, as well as sotrovimab as latest addition to this group. On the other hand, EMA has bamlanivimab and etesevimab, regdanvimab, casirivimab and imdevimab (REGN-COV2) and sotrovimab under rolling review to date.
This work outlines the most important techniques to obtain mAbs, delivers the available information of the mAbs that are currently approved for use in SARS-CoV-2 virus infection, and discusses the formulation and stability aspects of these protein formulations
| Item Type: | Conference or Workshop Item (Lecture) |
|---|---|
| Subjects: | Medical and Health Sciences > Health biotechnology Medical and Health Sciences > Health sciences Medical and Health Sciences > Other medical sciences |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Katarina Smilkov |
| Date Deposited: | 21 Oct 2021 09:17 |
| Last Modified: | 21 Oct 2021 09:17 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/28610 |
Actions (login required)
 |
View Item |